Corxel Pharmaceuticals
China · Biotech · Healthtech
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
A pipeline built around small molecules
CORXEL develops and licenses drug candidates for cardiometabolic disease. Its lead assets include CX11, an oral GLP-1 receptor agonist being developed for obesity and diabetes, and JX10, an investigational treatment for acute ischemic stroke. The company combines clinical development, regulatory and commercialization expertise to move licensed and internally developed programs through trials.
Development across regional markets
The group operates through separate subsidiaries. Corxel Pharmaceuticals, Inc. handles business outside China and develops the pipeline for markets outside Greater China. The broader group maintains offices in Hong Kong, Shanghai and Beijing, alongside its U.S. office in New Jersey.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series D1 | ≤$287M | Adage Capital Management — ParticipantHBM Healthcare Investments — ParticipantHengdian Group Capital — ParticipantInvus — ParticipantRA Capital Management — ParticipantRTW Investments — ParticipantSilverArc Capital — ParticipantSR One — ParticipantSymBiosis — ParticipantTCG Crossover — Participant |